Definitive Contract HHSN261201100069C

<p>The National Cancer Institute (NCI) awarded a $249,792 Small Business Innovation Research (SBIR) Phase I contract to Biotex, Inc. to develop &quot;Instruments and Devices that Preserve Molecular Profiles in Tumors&quot; under SBIR Topic 257. The contract is a firm-fixed-price definitive contract with a period of performance ending on June 30, 2010. This SBIR contract supports the NCI's research objectives related to advancing cancer diagnostics and therapeutics.</p>

The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanotarget LLC for the development of a nanoparticle CD8 T cell regimen for cancer therapy. The firm-fixed-price contract has a ceiling value of $174,251 and a period of performance ending on May 31, 2010. No subcontractors are mentioned. The SBIR program supports research and development of innovative technologies by small businesses to address key...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract, valued at $199,981, is for the development of nanoparticle-enabled single cell mass spectrometry technology for the detection of rare cells, under SBIR Topic 266. As a small business, Nanocomposix has been awarded previous prime...

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Nanoscale Corporation. The $831,900 contract is for the development of &quot;functionalized bimagnetic core/shell Fe/Fe3O4 stealth nanoparticles&quot; for the diagnosis and treatment of cancer. The contract includes two major subcontractors - Xenometrics, LLC, which will conduct toxicology testing, and the...

This is a $198,641 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Nanocellect Biomedical Inc., a for-profit biotechnology company. The contract is for the development of a &quot;CTC Label and Capture by Lab-on-a-Chip Flow-Cytometry&quot; solution, which aligns with the NCI's research interests. Nanocellect Biomedical is an innovative provider of automated cell analysis, sorting, and dispensing equipment and services, with a strong...

<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Oncotherapeutica, Inc. for the development of a &quot;Prostate Cancer Selective Radioactive Prodrug&quot;. This $298,882 Firm Fixed Price contract was awarded on September 19, 2016 and has a completion date of November 18, 2017. The contract is designated as a Total Small Business set-aside.</p>

The National Cancer Institute awarded a $1,995,119 firm-fixed-price Phase II SBIR contract to Boston Cell Standards Inc., a for-profit manufacturer of medical devices, diagnostics, and related services. The contract, which is set aside for small businesses, is to develop quantitative traceable reference materials for use in cancer detection and diagnostics. This award builds on a previous $385,889 Phase I SBIR contract with the National Cancer Institute. Boston Cell Standards has also received...